Literature DB >> 26161545

An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics".

Edward S Dove1, I Ömer Barlas2, Kean Birch3, Catharina Boehme4, Alexander Borda-Rodriguez5,6, William M Byne7, Florence Chaverneff8, Yavuz Coşkun9, Marja-Liisa Dahl10, Türkay Dereli11, Shyam Diwakar12, Levent Elbeyli13, Laszlo Endrenyi14, Belgin Eroğlu-Kesim15, Lynnette R Ferguson16, Kıvanç Güngör17, Ulvi Gürsoy18, Nezih Hekim19, Farah Huzair20, Kabeer Kaushik21, Ilona Kickbusch22, Olcay Kıroğlu23, Eugene Kolker24,25,26,27, Eija Könönen18, Biaoyang Lin28,29, Adrian Llerena30, Faruk Malhan31, Bipin Nair12, George P Patrinos32, Semra Şardaş33, Özlem Sert34, Sanjeeva Srivastava35, Lotte M G Steuten36,37, Cengiz Toraman38, Effy Vayena39, Wei Wang40,41, Louise Warnich42, Vural Özdemir9,11,12,26,38.   

Abstract

Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for promulgating an "Essential Diagnostics List." Additionally, we explain the ways in which adopting a vision for "Health in All Policies" could link essential diagnostics with robust and timely societal outcomes such as sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First, we propose the need for a new, "see through" taxonomy for knowledge-based innovation as we transition from the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20(th) century to the anticipated knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods, quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory focus on innovation is crucial and applicable across all sectors, including public, private, or public-private partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values, and social systems. By making the value systems embedded in scientific design and knowledge co-production transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global health community to consider the necessary qualities of good governance for 21st century organizations that will embark on developing essential diagnostics. These have importance not only for science and knowledge-based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today and for future generations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26161545     DOI: 10.1089/omi.2015.0075

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  4 in total

1.  Roadmap for Establishing Large-Scale Genomic Medicine Initiatives in Low- and Middle-Income Countries.

Authors:  George P Patrinos; Emmanouil Pasparakis; Erasmia Koiliari; Alexandre C Pereira; Tábita Hünemeier; Lygia V Pereira; Christina Mitropoulou
Journal:  Am J Hum Genet       Date:  2020-10-01       Impact factor: 11.025

2.  The availability and affordability of orphan drugs for rare diseases in China.

Authors:  Shiwei Gong; Yingxiao Wang; Xiaoyun Pan; Liang Zhang; Rui Huang; Xin Chen; Juanjuan Hu; Yi Xu; Si Jin
Journal:  Orphanet J Rare Dis       Date:  2016-02-27       Impact factor: 4.123

Review 3.  China-Africa Health Development Initiatives: Benefits and Implications for Shaping Innovative and Evidence-informed National Health Policies and Programs in Sub-saharan African Countries.

Authors:  Ernest Tambo; Chidiebere E Ugwu; Yayi Guan; Ding Wei; Zhou Xiao-Nong
Journal:  Int J MCH AIDS       Date:  2016

4.  Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.

Authors:  Luyao Qiao; Xin Liu; Junmei Shang; Wei Zuo; Tingting Xu; Jinghan Qu; Jiandong Jiang; Bo Zhang; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-09-10       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.